Cargando…

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

Because no currently available vaccine can prevent HIV infection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combating the HIV pandemic(1,2). Long-acting ARVs promise to build on the success of current PrEP strategies, which must be taken daily, by reducing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vidal, Samuel J., Bekerman, Elena, Hansen, Derek, Lu, Bing, Wang, Kelly, Mwangi, Judy, Rowe, William, Campigotto, Federico, Zheng, Jim, Kato, Darryl, Chandrashekar, Abishek, Barrett, Julia, Patel, Shivani, Wan, Huahua, Anioke, Tochi, Mercado, Noe B., Nkolola, Joseph P., Ferguson, Melissa J., Rinaldi, William J., Callebaut, Christian, Blair, Wade, Cihlar, Tomas, Geleziunas, Romas, Yant, Stephen R., Barouch, Dan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753592/ https://www.ncbi.nlm.nih.gov/pubmed/34875675 http://dx.doi.org/10.1038/s41586-021-04279-4

Ejemplares similares

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020)

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
por: Moldt, Brian, et al.
Publicado: (2022)

Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
por: Walker-Sperling, Victoria E. K., et al.
Publicado: (2022)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020)

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
por: Cadena, Anthony M., et al.
Publicado: (2021)

A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
por: Nkolola, Joseph P., et al.
Publicado: (2022)

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia
por: Nishimura, Yoshiaki, et al.
Publicado: (2020)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid
por: Peng, Ke, et al.
Publicado: (2014)

539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans
por: Zheng, Jim, et al.
Publicado: (2018)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Search for small molecule activators of latent HIV
por: Geleziunas, Romas, et al.
Publicado: (2012)

Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
por: Chandrashekar, Abishek, et al.
Publicado: (2021)

Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2013)

Human Immunodeficiency Virus Type 1-Associated Cd4 Downmodulation
por: Geleziunas, Romas, et al.
Publicado: (1994)

PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy
por: Bekerman, Elena, et al.
Publicado: (2019)

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
por: Yu, Jingyou, et al.
Publicado: (2022)

Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques
por: Dagotto, Gabriel, et al.
Publicado: (2021)

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
por: Pauthner, Matthias G., et al.
Publicado: (2019)

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
por: Collier, Ai-ris Y., et al.
Publicado: (2021)

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
por: He, Xuan, et al.
Publicado: (2022)

Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts
por: Collier, Ai-ris Y., et al.
Publicado: (2021)

Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir
por: Kumar, Mithra R., et al.
Publicado: (2023)

Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
por: Zheng, Qi, et al.
Publicado: (2012)

Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4(+) T Cells
por: Obregon-Perko, Veronica, et al.
Publicado: (2020)

Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
por: Vidal, Samuel J., et al.
Publicado: (2021)

Prevention of SHIV transmission by topical IFN-β treatment
por: Veazey, Ronald S., et al.
Publicado: (2016)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques
por: Jacob-Dolan, Catherine, et al.
Publicado: (2023)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

Shiv Nadar School students visit CERN
por: Poulaillon, Jimmy, et al.
Publicado: (2023)

Oral Vaccination Approaches for Anti-SHIV Immunity
por: Velarde de la Cruz, Erandi, et al.
Publicado: (2021)

Study of Marine Natural Products Including Resorcyclic Acid Lactones from Humicola fuscoatra That Reactivate Latent HIV-1 Expression in an in Vitro Model of Central Memory CD4+ T Cells
por: Mejia, Eric J., et al.
Publicado: (2014)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

In memory of a Legend: Dr. Shiv Shankar Gupta
por: Chandra, Dinesh
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2n9camh6rl3r3muhmooerdl903